MLMeiting Li

Meiting Li

*This is an algorithmically generated author record based on publicly available information.

Meiting Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Tianyun Hou

    Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

    7 shared publications
  • Wei-Guo Zhu

    Institute of Gerontology, The First Affiliated Hospital of Shenzhen University; Department of Biochemistry and Molecular Biology, International Cancer Center, Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Shenzhen University Medical School, Shenzhen University, Shenzhen, China

    7 shared publications
  • Qian Zhu

    Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Medicine, Shenzhen University, Shenzhen 518060, China

    6 shared publications
  • Chaohua Liu

    Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

    5 shared publications
  • Qiaoyan Yang

    Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

    5 shared publications
  • Xiaopeng Lu

    Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Medicine, Shenzhen University, Shenzhen 518060, China

    5 shared publications

Latest Publications

  • Open Access

    KAT8 acetylation-controlled lipolysis affects the invasive and migratory potential of colorectal cancer cells

    by Bingquan Qiu, Shen Li, Meiting Li, Shuo Wang, Guanqun Mu, Keyu Chen, Meng Wang, Wei-Guo Zhu, Weibin Wang, Jiadong Wang, et al.

    Epigenetic mechanisms involved in gene expression play an essential role in various cellular processes, including lipid metabolism. Lysine acetyltransferase 8 (KAT8), a histone acetyltransferase, has been reported to mediate de novo lipogenesis by acetylating fatty acid synthase. However, the effect of KAT8 on lipolysis is unclear. Here, we report a novel mechanism of KAT8 on lipolysis involving in its acetylation by general control non-repressed protein 5 (GCN5) and its deacetylation by Sirtuin 6 (SIRT6). KAT8 acetylation at K168/175 residues attenuates the binding activity of KAT8 and inhibits the recruitment of RNA pol II to the promoter region of the lipolysis-related genes adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), subsequently down-regulating lipolysis to affect the invasive and migratory potential of colorectal cancer cells. Our findings uncover a novel mechanism that KAT8 acetylation-controlled lipolysis affects invasive and migratory potential in colorectal cancer cells.


  • Open Access

    CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis

    by Chaohua Liu, Qiaoyan Yang, Qian Zhu, Xiaopeng Lu, Meiting Li, Tianyun Hou, Zhiming Li, Ming Tang, Yinglu Li, Hui Wang, et al.

    Background and Aim: DOT1L regulates various genes involved in cancer onset and progression by catalyzing H3K79 methylation, but how DOT1L activity itself is regulated is unclear. Here, we aimed to identify specific DOT1L post-translational modifications that might regulate DOT1L activity and thus impact on colorectal cancer (CRC) progression.


  • A specific assay for JmjC domain-containing lysine demethylase and its application to inhibitor screening

    by He Wen, Guo Li, Yongcan Chen, Meiting Li, Yafei Lv, Zhiming Li, Yinglu Li, Tianyun Hou, Hui Wang, Chaohua Liu, et al.


  • Open Access

    PKCζ Phosphorylates SIRT6 to Mediate Fatty Acid β-Oxidation in Colon Cancer Cells

    by Tian Gao, Meiting Li, Guanqun Mu, Tianyun Hou, Wei-Guo Zhu, Yang Yang


  • Open Access

    p53 cooperates with SIRT6 to regulate cardiolipin de novo biosynthesis

    by Meiting Li, Tianyun Hou, Tian Gao, Xiaopeng Lu, Qiaoyan Yang, Qian Zhu, Zhiming Li, Chaohua Liu, Guanqun Mu, Ge Liu, et al.

    The tumor suppressor p53 has critical roles in regulating lipid metabolism, but whether and how p53 regulates cardiolipin (CL) de novo biosynthesis is unknown. Here, we report that p53 physically interacts with histone deacetylase SIRT6 in vitro and in vivo, and this interaction increases following palmitic acid (PA) treatment. In response to PA, p53 and SIRT6 localize to chromatin in a p53-dependent manner. Chromatin p53 and SIRT6 bind the promoters of CDP-diacylglycerol synthase 1 and 2 (CDS1 and CDS2), two enzymes required to catalyze CL de novo biosynthesis. Here, SIRT6 serves as a co-activator of p53 and effectively recruits RNA polymerase II to the CDS1 and CDS2 promoters to enhance CL de novo biosynthesis. Our findings reveal a novel, cooperative model executed by p53 and SIRT6 to maintain lipid homeostasis.


  • Open Access

    Destabilization of linker histone H1.2 is essential for ATM activation and DNA damage repair

    by Zhiming Li, Yinglu Li, Ming Tang, Bin Peng, Xiaopeng Lu, Qiaoyan Yang, Qian Zhu, Tianyun Hou, Meiting Li, Chaohua Liu, et al.

    Linker histone H1 is a master regulator of higher order chromatin structure, but its involvement in the DNA damage response and repair is unclear. Here, we report that linker histone H1.2 is an essential regulator of ataxia telangiectasia mutated (ATM) activation. We show that H1.2 protects chromatin from aberrant ATM activation through direct interaction with the ATM HEAT repeat domain and inhibition of MRE11-RAD50-NBS1 (MRN) complex-dependent ATM recruitment. Upon DNA damage, H1.2 undergoes rapid PARP1-dependent chromatin dissociation through poly-ADP-ribosylation (PARylation) of its C terminus and further proteasomal degradation. Inhibition of H1.2 displacement by PARP1 depletion or an H1.2 PARylation-dead mutation compromises ATM activation and DNA damage repair, thus leading to impaired cell survival. Taken together, our findings suggest that linker histone H1.2 functions as a physiological barrier for ATM to target the chromatin, and PARylation-mediated active H1.2 turnover is required for robust ATM activation and DNA damage repair.


  • G9a coordinates with the RPA complex to promote DNA damage repair and cell survival

    by Qiaoyan Yang, Qian Zhu, Xiaopeng Lu, Yipeng Du, Linlin Cao, Changchun Shen, Tianyun Hou, Meiting Li, Zhiming Li, Chaohua Liu, et al.

    Significance: The G9a histone methyltransferase primarily regulates the expression of genes associated with cancer development in cancer cells, but it has also been implicated in mediating the DNA damage response. Here, we confirmed a role for G9a in DNA damage repair following double-strand breaks. G9a is recruited to chromatin as a result of casein kinase 2-mediated phosphorylation, where it directly interacts with replication protein A (RPA). G9a binding to RPA modulates RPA and Rad51 foci formation and permits efficient homologous recombination. This molecular mechanism renders cancer cells more resistant to radiation and chemotherapeutics. Our improved understanding of the molecular function of G9a may help with the future design of G9a inhibitors and G9a-based DNA damage agents as cancer therapeutics.


  • Open Access

    SET7/9 regulates cancer cell proliferation by influencing β‐catenin stability

    by Changchun Shen, Donglai Wang, Xiangyu Liu, Bo Gu, Yipeng Du, Fu‐Zheng Wei, Lin‐Lin Cao, Boyan Song, Xiaopeng Lu, Qiaoyan Yang, et al.

    β‐Catenin, which is a key mediator of the wingless‐integration site (Wnt)/β‐catenin signaling pathway, plays an important role in cell proliferation, cell fate determination, and tumorigenesis, by regulating the expression of a wide range of target genes. Although a variety of posttranslational modifications are involved in β‐catenin activity, the role of lysine methylation in β‐catenin activity is largely unknown. In this study, su(var)3‐9, enhancer‐of‐zeste, trithorax (SET) domain‐containing protein 7 (SET7/9), a lysine methyltransferase, interacted with and methylated β‐catenin, as demonstrated both in vitro and in vivo. The interaction and methylation were significantly enhanced in response to H 2 O 2 stimulation. A mutagenesis assay and mass spectrometric analyses revealed that β‐catenin was monomethylated by SET7/9 at lysine residue 180. Methylated β‐catenin was easily recognized by Phosphokinase glycogen synthase kinase (GSK)‐3β for degradation. Consistent with this finding, the mutated β‐catenin (K180R) that cannot be methylated exhibited a longer half‐life than did the methylated β‐catenin. The consequent depletion of SET7/9 by shRNA or the mutation of the β‐catenin (K180R) significantly enhanced the expression of Wnt/β‐catenin target genes such as c‐myc and cyclin D1 and promoted the growth of cancer cells. Together, these results provide a novel mechanism by which Wnt/ β‐catenin signaling is regulated in response to oxidative stress.—Shen, C., Wang, D., Liu, X., Gu, B., Du, Y., Wei, F.‐Z., Cao, L.‐L., Song, B., Lu, X., Yang, Q., Zhu, Q., Hou, T., Li, M., Wang, L., Wang, H., Zhao, Y., Yang, Y., Zhu, W.‐G. SET7/9 regulates cancer cell proliferation by influencing β‐catenin stability. FASEB J. 29, 4313‐4323 (2015). www.fasebj.org